Publications

Randomized Phase Iii Study of Lenalidomide Versus Placebo in Rbc Transfusion-Dependent Patients With Lower-Risk Non-Del(5Q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents

AuthID
P-00K-T5A

Author(s)

Santini, V

Giagounidis, A

Mufti, GJ

Buckstein, R

Mittelman, M

Platzbecker, U

[+2]·

del Canizo, C

Gattermann, N

Ozawa, K

Risueno, A

MacBeth, KJ

Zhong, JH

Seguy, F

Hoenekopp, A

Beach, CL

Fenaux, P

View all authors

Document Type

Article

Year published

2016

Published

in JOURNAL OF CLINICAL ONCOLOGY, ISSN: 0732-183X

Volume: 34, Issue: 25, Pages: 2988-+ (11)

Indexing

Wos^®

Scopus^®

Crossref^®

Google Scholar^®

Metadata
Sources

Publication Identifiers

DOI: 10.1200/jco.2015.66.0118

SCOPUS: 2-s2.0-84983628285

Wos: WOS:000382470100009

Source Identifiers

ISSN: 0732-183X

Export Publication Metadata

Marked List

Add to Marked List

Info

At this moment we don't have any links to full text documens.

All authors

Name Order	Name	Name Order	Name	Name Order	Name
1	Santini, V;	2	Almeida, A;	3	Giagounidis, A;
4	Groepper, S;	5	Jonasova, A;	6	Vey, N;
7	Mufti, GJ;	8	Buckstein, R;	9	Mittelman, M;
10	Platzbecker, U;	11	Shpilberg, O;	12	Ram, R;
13	del Canizo, C;	14	Gattermann, N;	15	Ozawa, K;
16	Risueno, A;	17	MacBeth, KJ;	18	Zhong, JH;
19	Seguy, F;	20	Hoenekopp, A;	21	Beach, CL;
22	Fenaux, P;

Randomized Phase Iii Study of Lenalidomide Versus Placebo in Rbc Transfusion-Dependent Patients With Lower-Risk Non-Del(5Q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents

Useful Links

Get Help

Federated Authentication (Click on the image)

Randomized Phase Iii Study of Lenalidomide Versus Placebo in Rbc Transfusion-Dependent Patients With Lower-Risk Non-Del(5Q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents

Useful Links

Get Help